Ongoing research aims to better understand the complex roles of the ER and UPR in cancer, identify biomarkers for predicting response to ER-targeted therapies, and develop more selective and potent inhibitors. Combining ER-targeted therapies with other treatments, such as chemotherapy, immunotherapy, or targeted therapy, may enhance their efficacy and reduce the likelihood of resistance. As our understanding of the ER's role in cancer deepens, it will pave the way for novel therapeutic strategies and improved patient outcomes.
